Skip to main content
Sign In

Vu Nguyen, MD

Vu Nguyen, MD
Vu Nguyen, MD
University of Colorado School of Medicine
  • Assistant Professor of Medicine


Contact information

Anschutz Medical Campus
12700 East 19th Ave, Room 9122
Research Complex 2, Campus Box B170
Aurora, CO  80045

Dr. Nguyen completed his bachelor’s degree at the University of California, Berkeley, and medical education at the Albert Einstein College of Medicine.  After medical school, he trained in Internal Medicine at the University of California, Davis, followed by a fellowship in Hematology and Oncology at the University of California, San Francisco.  He went onto a postdoctoral research fellowship and was an Instructor in Hematopoietic Stem Cell Transplantation at Stanford University, where he worked closely with leading investigators in the fields of cancer and transplant immunology.  In 2008, he joined the faculty at the University of Chicago in 2008 where he developed his current line of research and was recruited to the University of Colorado in 2012.

Dr. Nguyen has been successful in establishing a dual-career role of both a physician and laboratory scientist.  He has served as a manuscript reviewer for Blood, Leukemia & Lymphoma, Journal of Immunology, and Clinical Advances in Hematology & Oncology. 
  • B.A., Biochemistry. University of California, Berkeley, CA 
  • M.D., Albert Einstein College of Medicine, Bronx, NY
  • Residency, University of California at Davis, CA
  • Clinical Fellow, Division of Hematology-Oncology, UCSF, San Francisco, CA
  • Postdoctoral Fellow, Division of Hematopoietic Cell Transplantation, Stanford University, CA
Dr. Nguyen’s research lab is investigating the immunology of hematopoietic stem cell transplantation (HSCT) for leukemia and lymphoma.  In particular, the lab is studying the immunological interaction between the HSCT recipient and the gut commensal bacteria (microbiota) and its genome (microbiome) to understand the mechanisms that mediates graft-versus-host disease (GVHD), stem cell engraftment, and immune reconstitution. The long-term goal of the research is to identify specific microbiota and unique biological pathways involved in protecting versus promoting complications following HSCT and to develop preventive and therapeutic strategies that manipulate the microbiota and its microbiome to improve outcomes for patients undergoing HSCT.

Clinically, Dr. Nguyen is focused on lymphoma and chronic lymphocytic leukemia, as well as autologous and allogeneic hematopoietic stem cell transplantation.  He is also helping to build a clinical research portfolio that allows therapeutic options for our patients. 

Selected Peer Reviewed Publications

1. Zeiser R, Nguyen VH, Beihack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS. (2006). Inhibition of CD4+CD25+ regulatory T cell function by calcineurin dependent interleukin-2 production.  Blood 108(1), 390-9. PMID: 16522809
2. Nguyen VH, Zeiser R, Negrin RS. (2006).  Role of naturally arising regulatory T cells in hematopoietic cell     transplantation. 2006. Biol Blood Marrow Transplant 12(10), 995-1009. PMID: 17084366
3. Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS.  (2007). Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood 109(5), 2225-33. PMID: 17068147
4. Nguyen VH, Zeiser R, daSilva D, Chang DS, Beilhack A, Contag CH, Negrin RS. (2007). In vivo dynamics of regulatory T cell trafficking and survival predict effective strategies to control of graft-versus-host disease following allogeneic transplantation.  Blood 109(6), 2649-56. PMID: 17095616
5. Nguyen VH, Shashidhar S, Chang DS, Ho L, Kambham N, Bachmann M, Brown JMY, Negrin RS. (2008). The impact of regulatory T cells on T cell immunity following hematopoeitic cell transplantation.  Blood 111(2), 945-53. PMID: 17916743
6. Nguyen V, van Besien K. (2008) Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft-versus-leukemia effects?  Leuk Lymphoma 49(9),1651-2. PMID: 18798096
7. Sharma M, Moore J, Nguyen V, Van Besien K.  (2009).  Fatal CMV pneumonitis in a lymphoma patient treated with rituximab.  Am J Hematol 84(9), 614-6. PMID: 19676117
8. Nguyen VH.  (2011) Balancing act for Treg immunotherapy.  Blood 117(10), 2751-2. PMID: 21393500
9. Horch M and Nguyen VH. (2011). Regulatory T cell immunotherapy for allogeneic hematopoietic stem cell transplantation. Therapeutic Advances in Hematology 3(1), 29-44. PMID: 23556110  
10. van Besien K, Stock W, Rich E, Odenike O, Godley L, O’Donnell P, Kline J, Nguyen V, Cerro P, Larson RA. Artz AS. (2011). Phase I-II study of clofarabine-melphalan-alemtuzumab condititioning for allogeneic hematopoietic cell transplantation.  Biol Blood Marrow Transplant 18(6):913-21. PMID: 22079470
11. Murphy S and Nguyen VH. (2011). Gut microflora and innate immunity in graft-versus-host disease. Leuk     Lymphoma 52(10), 1844-56. PMID: 21663498
12. Liu H, Rich E, Godley L, Odenike O, Joseph L, Kline J, Nguyen V, Cunningham J, Larson RA, Del Cerro P, Schroeder L, Pape L, Stock W,  Wickrema A, Artz AS, van Besien K. (2011). Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment and durable remissions in hematological malignancies.  Blood 118(24), 6438-45. PMID: 21976674
13. Richa EM, Kunnavakkam R,Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz AS. (2012) Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy 14(6),707-15. PMID: 22548695
14. Jain, N; Liu, HT; Artz, A; Anastasi, J; Odenike, O; Godley, L; Joseph, L; Marino, S; Kline, J; Nguyen, V; Schouten, V; Kunnavakkam, R; Larson, R; Stock, W; Ulaszek, J; Savage, P; Wickrema, A; van Besien,K. (2013) Immune Reconstitution After Combined Haploidentical And Umbilical Cord Blood Transplantation. Leuk Lymphoma 54(6):1242-9. PMID: 23088744

Publications Under Preparation

1. Tiwari N, Horch M, Chen J, Nguyen VH. CD30/CD30L signaling in Treg mediated suppression of T cell function in graft-versus-host disease. 

2. Horch M, Tiwari N, K, Zale E, Tretina K, Sahli N, Nguyen VH. CCR9 is critical for Treg protection of gut GVHD.

3. Horch M, Sahli N, Zale E, Johnson E, Lee H, Tretina K, Nadimpalli A, Antonopolous D, Nguyen VH.  Selected gut commensal subsets mediate GVHD via MyD88 pathway in nonhematopoietic cells.

Book Chapters

Nguyen VH and Rini B, Acute Myelogenous Leukemia; Chronic Myelogeous Leukemia; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Non-Hodgkin’s Lymphoma; Hodgkin’s Lymphoma,  in Brown C, Rini B eds. Holland-Frei Manual of Cancer Medicine, BC Decker, 1st edition (2005).